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Abstract: Protein Tyrosine Phosphatase gamma (PTPγ) is a receptor-like transmembrane protein belonging to the family 
of classical protein tyrosine phosphatases. PTPγ is known to regulate haematopoietic differentiation in a murine embry-
onic stem cells model. We have recently demonstrated that PTPγ mRNA is expressed in monocytes, tissue-localized myeloid 
dendritic cells and in both myeloid and plasmacytoid dendritic cells in peripheral blood. We now developed a PTPγ spe-
ciﬁ  c antibody that recognizes the protein by ﬂ  ow cytometry. PTPγ expression was detected in monocytes and both myeloid 
and plasmacytoid dendritic cells, while PMN showed a low but consistent staining in contrast with previous mRNA data. 
B cells were found to express the phosphatase while T cells were negative. In keeping with RNA data, PTPγ was detected 
in monocyte-derived dendritic cells and its expression rose upon LPS stimulation. Finally, we discovered that CD34
+ hae-
matopoietic precursors express high PTPγ level that drops during in vitro expansion induced by IL-3 and SCF growth fac-
tors. We therefore propose PTPγ as a new functionally regulated leukocyte marker whose role in normal and pathological 
context deserve further investigation. 
Keywords: Egg yolk immunoglobulin (IgY); human protein tyrosine phosphatase gamma (PTPγ); ﬂ  uorescence activated 
cell sorting (FACS); haematopoietic progenitors.
Abbreviations: IgY, Chicken egg yolk immunoglobulins; chPTPγ, Anti-PTPγ IgY antibody; PTPγ, human protein tyrosine 
phosphatase gamma.
Introduction
Protein phosphatases, together with kinases, control critical aspect of cellular signaling as they can 
modify the phosphorylation level of the cell, leading to pleiotropic effects on proliferation, differentia-
tion and survival (Andersen et al. 2001). Phosphatases can be divided in several families according to 
their substrate speciﬁ  city. Protein tyrosine phosphatases (PTPs) are further divided in two groups. Clas-
sical PTPs have phosphotyrosine as exclusive substrate, while dual speciﬁ  city phosphatases have a 
more open active site cleft, allowing them broader substrate speciﬁ  city (Tonks, 2003). PTPgamma 
(PTPγ) is a receptor-like transmembrane protein belonging to the family of classical PTPs; these enzymes 
can exist in transmembrane (receptor-type PTPs, RPTPs) or non-transmembrane form (described in 
http://ptp.cshl.edu/). RPTPs can be classiﬁ  ed in nine subtypes, according to the combination of structural 
motifs featuring in the N-terminal moiety; PTPγ belongs to the subtype V, characterized by the presence 
of a carbonic anhydrase-like and a ﬁ  bronectin type III domain at the N-terminus (Barnea et al. 1993). 
PTPγ has been proposed as a tumor suppressor gene whose expression is lost in various neoplastic 
diseases including renal cell carcinoma, lung, ovarian, breast and colorectal cancers (LaForgia et al. 
1993, Lubinski et al. 1994, Tsukamoto et al. 1992, van Niekerk and Poels, 1999, Liu et al. 2004, Wang 
et al. 2004, Vezzalini et al. 2007). Involvement in haemopoietic neoplasms has also been reported (van 
Doorn et al. 2005, Vezzalini et al. 2007). These data suggest a role for PTPγ in the molecular pathways 
that regulate proliferation and differentiation. Indeed, it has been shown that PTPγ is able to regulate 
haematopoietic differentiation in a murine embryonic stem cells model (Sorio et al. 1997). We have 
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recently demonstrated that PTPγ is expressed in 
peripheral blood myeloid and plasmacytoid 
dendritic cells as well as in monocytes where it is 
differentially regulated during in vitro differentia-
tion to dendritic cells or macrophages (Lissandrini 
et al. 2006). These latest ﬁ  ndings suggested the 
possibility that PTPγ represents a novel marker for 
myeloid cells in the haemopoietic system. Suitable 
antibodies that can be used in conjunction with 
lineage-restricted markers are not available. We 
recently developed a new chicken antibody targeted 
against the extra cellular domain of PTPγ suitable 
for ﬂ  ow cytometric analysis. Using this newly 
developed tool, we investigated the expression of 
this phosphatase in cell lines, peripheral blood 
samples and puriﬁ  ed haemopoietic precursors.
Materials and Methods
Cells, puriﬁ  cation and culture
The cell lines K562 (Andersson et al. 1979), HL-60 
(Gallagher et al. 1979), THP-1 (Tsuchiya et al. 
1980) and U937 (Sundstrom and Nilsson, 1976) 
were purchased from ATCC, ML-3 (Ohyashiki 
et al. 1986) was a kind gift from prof. M.A. 
Cassatella. Circulating human monocytes (>70% 
pure as assessed by expression of CD14), poly-
morphonuclear cells (>95% pure as assessed by 
CD15 expression) and lymphocytes (>95% pure 
as assessed by morphology and the lack of CD14) 
were purified by Percoll (Pharmacia Uppsala, 
Sweden) gradient centrifugation from leukocyte-
rich buffy coats obtained from human blood of 
healthy donors, as described elsewhere (Muzio 
et al. 1994). Immature monocyte-derived human 
dendritic cells (moDC) were obtained in vitro as 
previously described (Sozzani et al. 1997). Brieﬂ  y, 
puriﬁ  ed monocytes were cultured in RPMI 1640 
(2 × 10
6 cells/well) containing 10% heat-inacti-
vated FCS, 2mM glutamine and supplemented with 
50 ng/ml recombinant human GM-CSF and 
20 ng/ml recombinant human IL-4 (Peprotech, 
Rocky Hill, NJ) for 5–6 days. To induce matura-
tion, immature moDC were treated for 24 h with 
100 ng/ml LPS (Escherichia coli serotype 026: B6; 
Sigma, St. Louis MO) cells were subjected to ﬂ  ow 
cytometry analysis to assess the activation/matura-
tion status as previously described (Lissandrini 
et al. 2006). For CD34
+ cell selection, mononuclear 
cells were isolated from healthy donors buffy coats 
by Ficoll/Histopaque-1077 (Sigma-Aldrich, Milan, 
Italy) gradient centrifugation, rinsed and adher-
ence-depleted for one hour as described in (Zamai 
et al. 2000) with modiﬁ  cations. After removal of 
adherent cells, CD34
+ cells isolation was accom-
plished by immunomagnetical positive selection 
using magnetic beads coated with anti-CD34 mAb 
(CD34 isolation kit plus Vario-MACS system, 
Miltenyi Biotech, Bologna, Italy), according to the 
manufacturer’s instructions; cells were subjected 
to ﬂ  ow cytometry to assess purity and PTPγ expres-
sion. Purified CD34
+ cells (50,000/ml) were 
cultured for 3 days in 1 ml X-Vivo 20 (BioWittaker, 
Walkersville, MA, U.S.A) medium supplemented 
with 10% human AB serum in the presence of stem 
cell factor (SCF, 50 ng/ml) and IL-3 (10 ng/ml). 
All cytokines were purchased from Peprotech EC 
Ltd. (London, U.K.).
Antibody production
A chicken polyclonal antibody was raised against 
the sequence CZ NED EKE KTF TKD SDK DLK 
(residues #390–407 of extra cellular PTPγ 
sequence); produced IgY were afﬁ  nity puriﬁ  ed 
against the same sequence by Aves Labs (Tigard, 
OR, U.S.A). Pre-immune chicken IgY were 
collected and puriﬁ  ed from the same hen before 
the immunization process. Brieﬂ  y, the antigen was 
injected into the pectoral muscle of one American-
laying hen. Three booster injections containing 50 
µg of antigen mixed with incomplete Freund’s 
adjuvant were given at 2, 4 and 6 weeks. The eggs 
were collected daily and stored at 4 °C until the 
antibodies were extracted. The crude anti-PTPγ 
chicken IgY (chPTPγ) was further puriﬁ  ed using 
affinity column chromatography against the 
20-amino acid peptide. The non-speciﬁ  c proteins 
were washed from the column with washing buffer 
(0.1 M Tris– HCl, 0.5 M NaCl, pH 8.0), until the 
absorbance at 280 nm decreased to zero and the 
antibody was then eluted with a desorbing agent 
(0.1 M glycine, pH 3.0) 
PTPγ extra cellular domain-enriched 
supernatants production
293F cells (Invitrogen, Milan, Italy) were trans-
fected with a cDNA encoding for the extra cellular 
domain of PTPγ (pPTPx), containing the epitope 
of interest, cloned in pRC/CMV vector (Invitrogen, 
Milan, Italy). Transfection was achieved using 
Lipofectamine2000
TM (Invitrogen, Milan, Italy), 
diluted in OptiMEM
TM (Invitrogen, Milan, Italy), 
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according to the manufacturer’s optimized protocol 
for 293F cells. Positive cells were selected by 
plating transfected samples at about 10
5 cells/mL 
in RPMI 1640, 10% FBS, 1% Ultraglutamine, 
0.9 mg/mL G418 (Invitrogen, Milan, Italy) and 
incubating them in a humidiﬁ  ed atmosphere with 
5% CO2 at 37 °C. Exhaust medium was harvested 
every 48 hours and centrifuged 5 min at 350 × g 
to eliminate residual cells. After decanting, the 
supernatant was further centrifuged for 10 min at 
3000 × g to avoid cellular debris. The clariﬁ  ed 
pools were stored at –20 °C until needed. 
Western blot analysis
Equal amount of serum-free spent medium were 
mixed to 0.3 volumes of sample buffer (160 mM 
Tris, 20% Glycerol, 5% β-mercaptoethanol, 
4% SDS, 0.01% bromophenol blue) and loaded on 
a 10% polyacrylamide, 0.1% SDS gel. Gels were 
run for 1 hour at 200V, 14 mA in a Mini Protean 3 
Apparatus (Biorad, Milan, Italy) with 0.3%Tris, 
1.45% Glycine, 0.1% SDS running buffer, pH 8.9. 
After SDS-PAGE, gels were incubated for 20 min 
in transfer buffer (SDS running buffer, 20% 
methanol) and then electro-blotted on Hybond 
nitrocellulose (GE Healthcare, Milan, Italy) for 1 
hour at 100V, 120 mA in a Mini Trans-Blot Elec-
trophoretic Transfer Cell (Biorad, Milan, Italy); 
the homogeneous transfer of the samples on 
membranes was checked by Ponceau staining. For 
use with chPTPγ, membranes were saturated by 
incubation for 1 hour in 10% BlockHen II™ 
(AvesLabs, Tigard Oregon, U.S.A). After three 
washes in PBS, 0.05% tween
® 20 the membranes 
were incubated overnight with chPTPγ (1µg/ml) 
diluted in PBS, 0.1% tween
® 20. Membranes were 
then washed three times with PBS, 0.05% 
tween
® 20 and incubated for 1 hour with goat 
anti-chicken HRP (AvesLabs, Tigard Oregon, 
U.S.A; dilution 1:15,000). After three further 
washes, membranes were assayed with ECL (GE 
Healthcare, Milan, Italy). 
RNA extraction and northern blot
10 µg of total RNA was extracted from cell lines 
using the TRIzol
® reagent (Invitrogen, Milan, 
Italy) according to the manufacturer instructions 
and electrophoresed on a 1% formaldehyde-
agarose gel, blotted onto a Hybond N+ membrane 
and hybridized to 
32P-labeled cDNA probes 
prepared by random priming kit (Ready to-go DNA 
labeling Beads, Amersham Pharmacia Biotech, 
Uppsala, Sweden) using α-
32P dCTP (ICN, Costa 
Mesa, CA). The hybridization was performed as 
described (Sambrook et al. 1989). PTPγ, PTPζ, 
CD148 and actin cDNA were used as probes. PTPγ 
cDNA was ampliﬁ  ed by PCR from PTPγ pCR
®3.1 
plasmid (Invitrogen) using the following primers: 
forward 5’ CGT CAC CAG TCT CCT 3’, reverse 
5’ GAA GAG GCA GGA GAG 3’. PTPζ cDNA 
probe was obtained by reverse transcription of total 
RNA from human astrocytoma tissue and ampliﬁ  ed 
using the following primers: forward 5’ CTA GCT 
GAG GGG TTG GAA TC 3’, reverse 5’ GTG CCT 
GTT CTT CCA ACT CC 3’. CD148 cDNA probe 
was obtained by reverse transcription of total RNA 
from human peripheral blood granulocytes and 
ampliﬁ  ed using the following primers: forward 5’ 
TGC CAC ACA AGG ACC 3’, reverse 5’ TGA 
TTT GCT CCC CAC 3’. The identity of both 
probes was conﬁ  rmed by sequencing. 
Flow cytometry of puriﬁ  ed cells 
and whole blood
Purified cells and whole blood samples were 
stained with monoclonal anti-CD34 PE (clone 
AC136, Miltenyi Biotec, Bologna, Italy), anti-
CD14 PE, anti-CD15 FITC, anti-CD3 PE, anti-
CD19 PE, anti-CD1c biotin, anti-CD303 biotin, 
anti-CD1a FITC, anti-CD80 PE, anti-CD86 PE, 
anti-CD83 FITC (BioLegend, San Diego, CA) and 
the anti-PTPγ chicken IgY established in our lab. 
Biotinylated antibodies were detected with strep-
tavidin PE/Cy5 (BioLegend, San Diego, CA). As 
an isotypic control, pre-immune IgY and matched 
IgG1-PE or IgG2a-PE (BioLegend, San Diego, 
CA) were used. Brieﬂ  y, puriﬁ  ed cells were ﬁ  rst 
blocked with 10% v/v human serum (Invitrogen, 
Milan, Italy) for 15 minutes at RT, then incubated 
with chPTPγ (2 µg/10
6 cells) for 1 hour at RT. After 
one wash with staining buffer (5% FBS in PBS, 
0.1% NaN3), cells were stained with goat anti-
chicken Alexa488 (Invitrogen, Milan, Italy) for 30 
min at RT and/or with monoclonal antibodies for 
15 min at RT. Where biotinylated antibodies were 
included, a further wash was necessary, followed 
by an incubation with streptavidin PE/Cy5 for 15 
min at RT. Peripheral blood samples were ﬁ  rst 
incubated with 2 µg chPTPγ or pre-immune IgY 
for 1 hour at RT, then subjected to erythrocytes 
lysis by addition of 20 volumes of erythrocytes 
lysis solution (0.886% NH4Cl, 0.1% KHCO3, 
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0.006% EDTA) and incubation for 10 min at RT 
with gentle agitation. After addition of  0.5 volumes 
of staining buffer and pelleting of cells, a further 
wash with staining buffer was performed. Cells 
were then stained with goat anti-chicken Alexa488 
for 30 min at RT and/or with monoclonal antibodies 
as above described. Flow cytometry was performed 
on a Becton Dickinson FACScan
® ﬂ  ow cytometer. 
Analysis of ﬂ  ow cytometry data was performed 
with FCS Express V3 software (De Novo Soft-
ware) and geometric mean ﬂ  uorescence intensity 
(MFI) ratio between chPTPγ and isotype control 
antibodies has been used to evaluate PTPγ density 
of expression. 
Results
PTPγ expression in selected cell lines 
and antibody validation
The capability to recognize PTPγ by the chicken 
antibody was evaluated by western blot on the 
recombinant extra cellular domain. We loaded 
conditioned media from 293F cells transfected with 
either an empty vector or with a cDNA for the 
expression of  PTPγ extra cellular domain truncated 
at the level of the putative transmembrane region. 
The antibody speciﬁ  cally recognize the predicted 
120 KD band in the gel lane loaded with the super-
natant containing the recombinant extra cellular 
domain, being the supernatant derived from mock 
transfected cells negative. A similar, slight back-
ground was detectable in both the lanes (Fig. 1A). 
To validate the use of the antibody for ﬂ  ow cytom-
etry we ﬁ  rst analyzed PTPγ mRNA expression on 
a panel of cell lines by northern blot (Fig. 1B) and 
selected two cellular models: K562 completely 
lack PTPγ expression and was then transfected with 
both mock and PTPγ cDNA containing plasmids 
(K562 γ1). U937 was used as a positive control for 
native protein. As expected, chPTPγ speciﬁ  cally 
binds to U937 and K562 γ1 while K562 were 
negative (Fig. 1C). 
PTPγ is expressed in peripheral 
blood leukocytes
We then checked PTPγ expression in peripheral 
blood leukocytes. Our previous work showed that 
puriﬁ  ed monocytes express PTPγ mRNA, lympho-
cytes show a very low expression that we inter-
preted as residual (5%) monocytes contamination 
of the preparation, while polymorphonucleated 
cells (PMN) were negative (Lissandrini et al. 
2006). Flow cytometry (Fig. 2) conﬁ  rmed RNA 
data for monocytes. However individual staining 
of both B and T lymphocytes, obtained by CD19 
and CD3 double staining, showed that B cells 
express detectable amount of PTPγ. Surprisingly, 
PMN showed a slight positive staining for PTPγ 
in contrast with RNA data. This signal was consis-
tent and led us to hypothesize a residual expression 
of PTPγ protein on the surface of mature PMN in 
absence of active synthesis or its expression in a 
small subpopulation of granulocytes.
Staining of peripheral blood myeloid (CD1c
+/
CD19
–) and plasmacytoid (CD303
+) cells 
conﬁ  rmed the results previously obtained by RNA 
analysis (Lissandrini et al. 2006), with plasmacy-
toid DC showing a slightly stronger staining than 
myeloid DC.
PTPγ is expressed in monocyte-
derived dendritic cells (moDC) 
and further induced by maturation
As moDC expressed high PTPγ levels we wished 
to conﬁ  rm the expression and up-modulation of 
the protein upon induction of DC maturation by 
LPS. Cells were obtained from monocytes cultured 
in presence of IL-4 and GM-CSF and analyzed at 
day 6 of culture, after 24 h of incubation with or 
without LPS. In this case, ﬂ  ow cytometry with 
chPTPγ fully conﬁ  rmed previous data, showing 
that moDC express the phosphatase during differ-
entiation (geometric MFI ratio = 4.1) and that 
the expression is further enhanced upon LPS-
induced maturation (geometric MFI ratio = 22.7) 
(Fig 3A).
PTPγ is strongly expressed in puriﬁ  ed 
CD34
+ peripheral blood haematopoietic 
progenitors and down-modulated 
during in vitro expansion
We demonstrated that PTPγ expression cause a 
block in haemopoietic differentiation with an 
accumulation of cKIT/CD34
+ precursors in murine 
ES cells (Sorio et al. 1997) and, more recently, 
described high PTPγ expression in endothelial cells 
(Vezzalini et al. 2007). We therefore wished to 
examine the presence of PTPγ on CD34
+ cells, 
considered precursors for both haemopoietic and 
endothelial cells (Suda et al. 2000). We puriﬁ  ed 
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CD34
+ cells from leukocyte-rich buffy coats and 
analyzed the expression of this phosphatase. 
Freshly isolated CD34
+ cells showed the highest 
level of expression detected so far (geometric MFI 
ratio = 96.7 ± 9.75 SD, n = 4). After a three days 
treatment with SCF and IL-3 haematopoietic 
growth factors, known to induce proliferation and 
differentiation along erythro-myeloid lineage 
(Zamai et al. 2000), the levels of PTPγ expression 
decreases (geometric MFI ratio = 4.69 ± 1.50 SD, 
n = 4) (Fig. 3B). 
Discussion
The data here presented are aimed to complement 
those already exposed in our previous studies 
(Sorio et al. 1997, Lissandrini et al. 2006) regarding 
the expression of PTPγ in the haematopoietic 
system. The chPTPγ antibody recently developed 
by our group allowed us to move from mRNA 
expression data to surface labeling of cells and ﬂ  ow 
cytometry analysis. With few exceptions, the data 
conﬁ  rmed at the protein level what had been seen 
at the RNA level: PTPγ is preferentially expressed 
by monocytes and dendritic cells. With the sole 
exception of PMNs the mRNA levels appear to 
correlate rather well with protein levels, indicating 
a translational control of the expression levels of 
this phosphatase. Moreover, its expression levels 
are substantially modulated when cells are induced 
to proliferate or differentiate. We also demonstrate 
that PTPγ is expressed by B cells that represent a 
class of lymphocytes with the capability to act as 
antigen-presenting cells together with classic 
myeloid APCs. CD34
+ cells, precursors for both 
haemopoietic and endothelial cells (Suda et al. 
2000),  expressed PTPγ indicating that 
Figure 1A.) Western blot analysis of conditioned media with chPTPγ antibody: Nctr = medium from 293 cells transfected with empty vector, 
PTPγ = medium from 293 cells transfected with PTPγ extra cellular domain cDNA, producing and secreting a soluble 120 KD protein. 
B) Northern blot analysis of haemopoietic cell lines for PTPγ; PTPζ is the other member of subtype V receptor type tyrosine phosphatase 
and is used as a negative control; β-actin is showed for total RNA estimation. As a positive control for PTPζ hybridization we utilized human 
brain RNA on the same blot (data not shown). C) FACS analysis of K562, K562 transfected with PTPγ full-length cDNA (K562 γ1) and U937 
cell lines for PTPγ using chPTPγ antibody. Isotype control staining is showed in gray.
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undifferentiated progenitors are characterized by 
expression of this phosphatase. There might be the 
possibility that PTPγ is required for the mainte-
nance of the undifferentiated phenotype in haemo-
poietic precursors. This is suggested by previous 
data in the murine haemopoietic system where its 
overexpression inhibited erythro-myeloid differ-
entiation with the accumulation of cKIT/CD34
+ 
precursors (Sorio et al. 1997) and by the down 
modulation following in vitro culture with growth 
factors here observed. This latter ﬁ  nding, in agree-
ment with its proposed tumor suppressor function, 
would suggest an inverse correlation between 
haematopoietic proliferation/differentiation and 
PTPγ expression on haematopoietic progenitor 
cells. Of course it must be considered that the high 
expression observed on freshly puriﬁ  ed CD34
+ 
cells might also be due to the puriﬁ  cation proce-
dure. Of note is the observation that all the 
anaplastic large cell lymphomas and Reed-Stern-
berg cells in Hodgkin’s disease stained positive for 
PTPγ expression while only 14% of B cell 
neoplasms were found positive (Vezzalini et al. 
2007). This last result is of note given the expres-
sion detected in peripheral blood B cells and 
suggests different functions associated to speciﬁ  c 
lineages. 
We recently found high PTPγ expression in 
endothelial cells (Vezzalini et al. 2007). The 
role of PTPγ in vascular biology is completely 
unknown even if endothelial cells are known to 
express many transmembrane PTPs involved in 
the regulation of intercellular contacts of 
vascular wall cells (Kappert et al. 2005). Our 
findings suggest a distinct role of PTPγ expres-
sion in the haemopoietic system, where its 
expression is reduced following the initial steps 
of maturation along the erythro-myeloid series, 
and endothelial cells where it is found strongly 
expressed in mature cells.
Altogether our data validate the use of a novel 
antibody for the detection of PTPγ. The results also 
Figure 2. FACS analysis of peripheral blood PMN (CD15
+; CD14
–), T lymphocytes (CD3
+), B lymphocytes (CD19
+), monocytes (CD14
+), 
myeloid (CD1c
+/CD19
–) and plasmacytoid (CD303
+) DC using chPTPγ antibody. Isotype control is shown in gray, one representative 
experiment of eight from individual donors is shown.
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indicate that PTPγ has the features of a novel 
leukocyte marker whose expression is modulated 
during differentiation and maturation of speciﬁ  c 
leukocyte subsets. Although more work is needed 
in order to elucidate the biological function of this 
phosphatase, the evaluation of its expression might 
represent a useful tool for the characterization of 
haematopoietic, endothelial and stem cells 
subsets. 
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